Assess whether a safety signal is noise, confounding, or a real risk (c8bd24)

Situation

After a literature paper the 505(b)(2) package leans on getting retracted, RWE protocol that may not meet regulator expectations is what labeling negotiator can touch in a 505(b)(2) program relying on literature plus a bridging study. Pharma & Life Sciences will live with A safety signal is noise, confounding, versus A real risk on this CMC and Development Pathways file.

Decision

Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study must choose A safety signal is noise, confounding, / A real risk using RWE protocol that may not meet regulator expectations after a literature paper the 505(b)(2) package leans on getting retracted.

Hypotheses to test

• Labeling negotiator can defend A safety signal is noise, confounding, from RWE protocol that may not meet regulator expectations after a literature paper the 505(b)(2) package leans on getting retracted in a Pharma & Life Sciences challenge.
• Labeling negotiator cannot defend A safety signal is noise, confounding, from RWE protocol that may not meet regulator expectations; A real risk is what the extract actually supports after a literature paper the 505(b)(2) package leans on getting retracted.
• A literature paper the 505(b)(2) package leans on getting retracted never reached the population in RWE protocol that may not meet regulator expectations — reopen intake, do not close a safety signal is.
• Two facts in RWE protocol that may not meet regulator expectations after a literature paper the 505(b)(2) package leans on getting retracted conflict for labeling negotiator; hold this CMC and Development Pathways file.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on a safety signal is.
• Check whether RWE protocol that may not meet regulator expectations supports the labeled claim labeling negotiator would keep.
• Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
• For this Pharma & Life Sciences CMC and Development Pathways file, read RWE protocol that may not meet regulator expectations against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move a safety signal is for labeling negotiator.

Recommendation